Australian biotech firm Tryptamine Therapeutics Limited (ASX: TYP) secured A$6 million in new funding through a strategic placement. The placement, priced at A$0.02 per share, was backed by cornerstone investors that included Merchant Biotech Fund and biotech investor Daniel Tillett, who will join the company’s board as a non-executive director, …
